[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Sichuan Provincial People's Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":617},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,27,0,25,[9,52,80,112,138,161,188,212,238,262,289,313,334,357,376,403,424,444,465,488,506,525,547,568,594],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100641346","liposomal-amphotericin-b-for-invasive-fungal-disease-in-solid-organ-transplant-recipients-100641346",false,"NCT07656493","Liposomal Amphotericin B for Invasive Fungal Disease in Solid Organ Transplant Recipients","A Real-World Observational Study of the Effectiveness, Safety, and Therapeutic Drug Monitoring of Liposomal Amphotericin B in Solid Organ Transplant Recipients With Invasive Fungal Disease","LAMB-SOT","Inclusion Criteria:\n\n* Age 18 to 75 years.\n* Recipient of a solid organ transplant.\n* Diagnosis of invasive fungal disease (IFD) according to EORTC\u002FMSGERC criteria.\n* Receiving liposomal amphotericin B therapy as part of routine clinical care.\n* Provision of informed consent for prospective participants.\n\nExclusion Criteria:\n\n* Known hypersensitivity to amphotericin B formulations.\n* Severe hepatic dysfunction (ALT or AST \\>5× upper limit of normal, or total bilirubin \\>2× upper limit of normal).\n* Severe renal dysfunction requiring permanent discontinuation of antifungal therapy at baseline.\n* Pregnancy or breastfeeding.\n* Participation judged inappropriate by the investigator.","ALL","18 Years",{"count":21,"type":22},120,"ESTIMATED","OBSERVATIONAL","This real-world observational study aims to evaluate the effectiveness, safety, and therapeutic drug monitoring (TDM) of liposomal amphotericin B (L-AmB) in solid organ transplant recipients with invasive fungal disease (IFD). IFD is a major cause of morbidity and mortality in transplant recipients because of long-term immunosuppressive therapy and increased susceptibility to opportunistic fungal infections.\n\nThis is a single-center ambispective cohort study conducted at Sichuan Provincial People's Hospital. The study includes a prospective cohort of solid organ transplant recipients receiving L-AmB therapy and a historical control cohort treated with alternative systemic antifungal regimens. Clinical management and treatment decisions will be determined by treating physicians according to routine clinical practice, and no study-specific intervention will be introduced.\n\nThe study will collect information on demographic characteristics, transplant type, immunosuppressive regimens, fungal pathogens, infection sites, antifungal treatment strategies, laboratory findings, and clinical outcomes. Particular attention will be given to renal safety, electrolyte abnormalities, and therapeutic drug monitoring of liposomal amphotericin B. Plasma concentrations of L-AmB, treatment modifications, temporary treatment discontinuation, and concentration-related safety and effectiveness outcomes will be recorded during antifungal therapy.\n\nThe primary outcomes are the 28-day clinical response rate and 84-day all-cause mortality. Secondary outcomes include mycological clearance, acute kidney injury, electrolyte abnormalities, breakthrough fungal infection, treatment discontinuation due to adverse events, liposomal amphotericin B plasma concentrations, and the associations between L-AmB exposure and clinical outcomes or treatment-related toxicities.\n\nThe study is expected to provide real-world evidence regarding the effectiveness, safety, and pharmacokinetic characteristics of L-AmB in transplant recipients, support optimization of antifungal treatment strategies, and inform individualized dosing and monitoring approaches in this high-risk population.",[26,27,28],"Invasive Fungal Infection","Solid Organ Transplantation","Opportunistic Infections",[30,27,31,32,33,34,35,36,37,38],"Liposomal Amphotericin B","Invasive Fungal Disease","Antifungal Therapy","Tacrolimus","Cyclosporine","Therapeutic Drug Monitoring","Drug-Drug Interaction","Real-World Study","Transplant Infection","NOT_YET_RECRUITING","2026-06-19",{"date":42,"type":43},"2026-06-24","ACTUAL",{"date":45,"type":22},"2026-07-01",{"date":47,"type":22},"2028-06-30",{"name":49,"class":50},"Sichuan Provincial People's Hospital","OTHER",1,{"id":53,"slug":54,"hasResults":12,"nctId":55,"briefTitle":56,"officialTitle":56,"acronym":57,"eligibilityCriteria":58,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":59,"targetDuration":4,"studyType":61,"phases":62,"briefSummary":64,"conditions":65,"keywords":68,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":51},"100642062","phase-4-platelet-aggregation-function-guided-de-escalation-antiplatelet-therapy-in-patients-with-acute-ischemic-stroke-100642062","NCT07644234","Platelet Aggregation Function-Guided De-Escalation Antiplatelet Therapy in Patients With Acute Ischemic Stroke","PATH STROKE D","Inclusion Criteria:\n\n* 1.Age 18 years or older. 2.Diagnosis of acute non-disabling ischemic stroke or transient ischemic attack according to World Health Organization criteria, meeting one of the following definitions: acute non-disabling ischemic stroke, defined as a National Institutes of Health Stroke Scale score of 5 or lower at enrollment; or high-risk transient ischemic attack, defined as an ABCD2 score of 4 or higher.\n\n  3.Symptom onset within 48 hours. Onset time is defined as the interval from the last time the participant was known to be well to the time of combined administration of clopidogrel 300 mg and aspirin 100 mg.\n\n  4.MARADP \\\u003C35% measured 5 to 20 hours after combined antiplatelet treatment with clopidogrel 300 mg and aspirin 100 mg within 48 hours of symptom onset.\n\n  5.Planned treatment with aspirin plus clopidogrel or clopidogrel monotherapy for antiplatelet therapy.\n\n  6.Written informed consent provided by the participant or a legally authorized representative.\n\nExclusion Criteria:1.Imaging evidence of hemorrhagic stroke, hemorrhagic transformation, or another pathological brain disorder, such as vascular malformation, tumor, abscess, or another common non-ischemic brain disease such as multiple sclerosis.\n\n2.Minor stroke or transient ischemic attack caused by angioplasty or vascular surgery.\n\n3.Atrial fibrillation indicated by standard electrocardiography or typical physical signs of atrial fibrillation, including absolutely irregular rhythm, variable intensity of the first heart sound, or pulse deficit.\n\n4.A clear indication for anticoagulation, including suspected cardioembolism such as atrial fibrillation, known artificial heart valve, or suspected endocarditis.\n\n5.Intravenous thrombolysis, intra-arterial thrombolysis, mechanical thrombectomy, or any revascularization procedure performed after the index event or planned within 90 days.\n\n6.Use of antiplatelet agents other than aspirin or clopidogrel within 7 days before enrollment, such as ticagrelor or prasugrel.\n\n7.History of gastrointestinal bleeding, intracranial hemorrhage, recent major bleeding or blood transfusion, excluding minor hemoptysis or minor abnormal vaginal bleeding, or other bleeding disorder caused by coagulation dysfunction, such as purpura.\n\n8.Contraindication or intolerance to clopidogrel or aspirin, including known allergy; severe hepatic insufficiency or renal insufficiency; severe heart failure; coagulation disorder or history of systemic bleeding; history of thrombocytopenia or neutropenia; or history of drug-induced hematologic disease or hepatic dysfunction.\n\n9.Leukopenia, defined as white blood cell count \\\u003C2 x 10\\^9\u002FL, or thrombocytopenia, defined as platelet count \\\u003C100 x 10\\^9\u002FL.\n\n10.Use of heparin or oral anticoagulants within 10 days before enrollment. 11.Severe cardiac, pulmonary, hepatic, or renal dysfunction, or severe comorbid disease such as tumor, chronic airflow disease, severe dementia, or severe heart failure.\n\n12.Female participants of childbearing potential with a negative pregnancy test who refuse to use effective contraception, or women who are pregnant or breastfeeding.\n\n13.Poor compliance or inability to complete study requirements.\n\n\\-",{"count":60,"type":22},3836,"INTERVENTIONAL",[63],"PHASE4","This multicenter, prospective, open-label, randomized controlled trial will evaluate whether platelet aggregation function-guided de-escalation of antiplatelet therapy is non-inferior in efficacy and superior in safety compared with standard dual antiplatelet therapy in patients with acute minor ischemic stroke or high-risk transient ischemic attack who are sensitive to clopidogrel.\n\nParticipants who present within 48 hours of symptom onset and meet the eligibility criteria will receive loading doses of clopidogrel and aspirin, followed by platelet aggregation function testing. Eligible clopidogrel-sensitive participants will be randomized to receive either 7 days of dual antiplatelet therapy followed by clopidogrel monotherapy or standard 21-day dual antiplatelet therapy followed by single antiplatelet therapy. The primary efficacy outcome is new stroke within 90 days after randomization.",[66,67],"Ischemic Stroke","Transient Ischemic Attack",[69,66,70,71],"Antiplatelet de-escalation","Platelet function tests","RCT","2026-06-08",{"date":74,"type":43},"2026-06-12",{"date":76,"type":22},"2026-06",{"date":78,"type":22},"2029-10",{"name":49,"class":50},{"id":81,"slug":82,"hasResults":12,"nctId":83,"briefTitle":84,"officialTitle":85,"acronym":86,"eligibilityCriteria":87,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":88,"enrollmentInfo":89,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":91,"conditions":92,"keywords":96,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":51},"100638447","muscle-ultrasound-for-sarcopenia-assessment-in-kidney-transplant-recipients-100638447","NCT07607236","Muscle Ultrasound for Sarcopenia Assessment in Kidney Transplant Recipients","A Prospective Observational Study of Multimodal Muscle Ultrasound for Sarcopenia Assessment in Kidney Transplant Recipients","KT-SARC","Inclusion Criteria:\n\n* Adult patients aged 18 years or older\n* Patients scheduled to undergo kidney transplantation\n* Ability to undergo muscle ultrasound and bioelectrical impedance analysis (BIA)\n* Ability to provide written informed consent\n\nExclusion Criteria:\n\n* Patients with severe limb deformity or conditions preventing muscle ultrasound assessment\n* Patients with implanted electronic devices contraindicating BIA assessment\n* Inability to complete study assessments","80 Years",{"count":90,"type":22},140,"This is a single-center prospective observational study designed to evaluate the effectiveness of multimodal muscle ultrasound for the assessment of sarcopenia in kidney transplant recipients. Adult patients undergoing kidney transplantation will undergo both muscle ultrasound and bioelectrical impedance analysis (BIA) at predefined time points before and after transplantation.\n\nThe primary objective is to evaluate the diagnostic performance of muscle ultrasound for sarcopenia assessment, including its correlation and agreement with BIA-derived skeletal muscle index (BIA-SMI), as well as its diagnostic accuracy. Secondary objectives include describing the longitudinal changes in sarcopenia prevalence and muscle-related parameters from the pre-transplant period to 1 year after transplantation.\n\nThe study aims to provide evidence for a convenient, noninvasive, radiation-free, and reliable method for sarcopenia assessment in kidney transplant recipients.",[93,94,95],"Sarcopenia","Kidney Transplantation","Muscle Wasting",[97,98,99,100,101,102,103],"Muscle Ultrasound","Bioelectrical Impedance Analysis","BIA-SMI","Kidney Transplant Recipient","Muscle Mass","Frailty","Prospective Cohort","2026-05-19",{"date":106,"type":43},"2026-05-26",{"date":108,"type":22},"2026-05-30",{"date":110,"type":22},"2028-01-30",{"name":49,"class":50},{"id":113,"slug":114,"hasResults":12,"nctId":115,"briefTitle":116,"officialTitle":117,"acronym":118,"eligibilityCriteria":119,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":120,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":122,"conditions":123,"keywords":128,"overallStatus":130,"whyStopped":4,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":131,"startDateStruct":133,"completionDateStruct":135,"leadSponsor":137,"locationsCount":51},"100637503","sulbactam-durlobactam-in-crab-infection-a-real-world-cohort-study-100637503","NCT07601711","Sulbactam-Durlobactam in CRAB Infection: A Real-World Cohort Study","This is a Single-center Real-world Observational Cohort Study of Sulbactam-Durlobactam for Carbapenem-Resistant Acinetobacter Baumannii Infections: Effectiveness, Safety, and Exposure-Response Analysis","SD-CRAB","Inclusion Criteria:\n\n* Age ≥18 years.\n* Hospitalized patients receiving anti-CRAB antimicrobial therapy, including:\n\n  1. patients with confirmed carbapenem-resistant Acinetobacter baumannii (CRAB) infection based on microbiological testing in combination with clinical evidence of infection; or\n  2. transplant recipients with donor-derived CRAB colonization or infection who receive early targeted antimicrobial therapy.\n* Treatment initiation time can be clearly determined.\n* Availability of clinical outcome data.\n\nExclusion Criteria:\n\n* Colonization without evidence of active infection.\n* Missing key clinical data.\n* Inability to determine treatment initiation time.\n* Pregnancy or lactation.\n* Patients considered unsuitable by investigators.",{"count":121,"type":22},200,"This is a multicenter real-world observational cohort study designed to evaluate the effectiveness and safety of sulbactam-durlobactam in patients with carbapenem-resistant Acinetobacter baumannii (CRAB) infections. Patients receiving sulbactam-durlobactam will be compared with those receiving other anti-CRAB regimens during the same period.\n\nThe primary outcomes are 28-day all-cause mortality and clinical failure. Secondary outcomes include microbiological clearance, recurrence, length of hospital and ICU stay, duration of mechanical ventilation, and adverse events.\n\nTo reduce confounding inherent in observational studies, propensity score methods, including matching and inverse probability weighting, will be applied. A nested therapeutic drug monitoring (TDM) sub-cohort will be established to explore the relationship between drug exposure and clinical outcomes.",[124,125,126,127],"Carbapenem-Resistant Acinetobacter Baumannii Infection","Bloodstream Infection","Pneumonia","Sepsis",[129],"CRAB Infection","RECRUITING",{"date":132,"type":43},"2026-05-22",{"date":134,"type":43},"2025-11-11",{"date":136,"type":22},"2027-11-11",{"name":49,"class":50},{"id":139,"slug":140,"hasResults":12,"nctId":141,"briefTitle":142,"officialTitle":142,"acronym":143,"eligibilityCriteria":144,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":145,"targetDuration":4,"studyType":61,"phases":147,"briefSummary":149,"conditions":150,"keywords":4,"overallStatus":130,"whyStopped":4,"lastUpdateSubmitDate":153,"lastUpdatePostDateStruct":154,"startDateStruct":156,"completionDateStruct":158,"leadSponsor":160,"locationsCount":51},"100581686","phase-3-precision-antiplatelet-therapy-guided-by-platelet-aggregation-function-in-patients-with-acute-ischemic-stroke-100581686","NCT06853535","Precision Antiplatelet Therapy Guided by Platelet Aggregation Function in Patients With Acute Ischemic STROKE","PATH STROKE C","Inclusion Criteria:\n\n1. Age ≥ 18 years old.\n2. Patients diagnosed with acute non-disabling ischaemic stroke or transient ischaemic attack (TIA) with moderate to high stroke risk in accordance with the WHO diagnostic criteria, defined as follows:\n\n   * Acute non-disabling ischaemic stroke: NIHSS score ≤ 5 at enrollment;\n   * TIA with moderate to high stroke risk: ABCD₂ score ≥ 4.\n3. Time from symptom onset ≤ 48 hours. (Definition of symptom onset time: the interval from the last time the patient was observed in a normal state to the time of co-administration of clopidogrel 300 mg and aspirin 100 mg.)\n4. MARADP ≥ 35% measured at 5-20 hours after the patient received antiplatelet therapy with co-administration of clopidogrel 300 mg and aspirin 100 mg within 48 hours of symptom onset.\n5. Written informed consent signed by the patient or their legal representative.\n\nExclusion Criteria:\n\n1. Imaging examinations suggestive of hemorrhagic stroke, hemorrhagic transformation, or other pathological cerebral disorders, such as vascular malformation, tumor, abscess, or other common non-ischemic cerebral diseases (e.g., multiple sclerosis).\n2. Minor stroke\u002FTIA induced by angioplasty or vascular surgery.\n3. Routine electrocardiogram (ECG) suggestive of atrial fibrillation (AF), or physical examination findings of typical AF signs including completely irregular cardiac rhythm, variable intensity of the first heart sound, and pulse deficit.\n4. Having definite indications for anticoagulant therapy (suspected cardiogenic embolism, e.g., atrial fibrillation, known artificial heart valve, suspected endocarditis, etc.).\n5. Patients who have received intravenous thrombolysis, intra-arterial thrombolysis, mechanical thrombectomy, or any revascularization surgery after the current onset, or plan to receive such procedures within 90 days.\n6. Use of antiplatelet agents other than aspirin and clopidogrel (e.g., ticagrelor, prasugrel) within 7 days.\n7. History of gastrointestinal bleeding, intracranial hemorrhage, massive hemorrhage or blood transfusion in the recent period (excluding mild hemoptysis and mild abnormal vaginal bleeding), or history of other hemorrhagic diseases caused by coagulation dysfunction (e.g., purpura).\n8. Having contraindications to or intolerance of clopidogrel, ticagrelor, or aspirin, including:\n\n   * Known history of hypersensitivity;\n   * Severe hepatic or renal insufficiency (definition of severe hepatic insufficiency: ALT \\> 2× upper limit of normal \\[ULN\\] or AST \\> 2× ULN; definition of severe renal insufficiency: creatinine \\> 1.5× ULN);\n   * Severe heart failure (NYHA Class Ⅲ or Ⅳ);\n   * Coagulation disorders or history of systemic hemorrhage;\n   * History of previous thrombocytopenia or neutropenia;\n   * History of previous drug-induced hematological diseases or hepatic dysfunction.\n9. Leukopenia (\\\u003C 2×10⁹\u002FL) or thrombocytopenia (\\\u003C 100×10⁹\u002FL).\n10. Use of heparin or oral anticoagulants within 10 days prior to enrollment.\n11. Patients with severe cardiac, pulmonary, hepatic, or renal insufficiency, and those with severe comorbidities (e.g., malignancy, chronic airflow limitation, severe dementia, severe heart failure).\n12. Women of childbearing age with a negative pregnancy test but who refuse to adopt effective contraceptive measures; pregnant or lactating women.\n13. Poor compliance, unable to cooperate with the requirements of the study.",{"count":146,"type":22},5138,[148],"PHASE3","The objective of this clinical trial is to evaluate the efficacy and safety of platelet aggregation function - guided precision anti - platelet therapy in patients with acute cerebral infarction. The main question it aims to answer is: among the cerebral infarction patients with possible clopidogrel resistance detected by platelet aggregation function tests, what is the efficacy and safety of using ticagrelor to replace the clopidogrel treatment regimen.",[151,152],"Acute Ischemic Stroke","Clopidogrel Resistance","2026-05-11",{"date":155,"type":43},"2026-05-12",{"date":157,"type":43},"2025-05-23",{"date":159,"type":22},"2027-12-31",{"name":49,"class":50},{"id":162,"slug":163,"hasResults":12,"nctId":164,"briefTitle":165,"officialTitle":166,"acronym":4,"eligibilityCriteria":167,"healthyVolunteers":168,"sex":18,"minAge":169,"maxAge":4,"enrollmentInfo":170,"targetDuration":4,"studyType":61,"phases":172,"briefSummary":173,"conditions":174,"keywords":176,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":181,"lastUpdatePostDateStruct":182,"startDateStruct":183,"completionDateStruct":185,"leadSponsor":187,"locationsCount":4},"100637307","phase-4-dexmedetomidine-nasal-spray-on-postoperative-delirium-in-elderly-thoracoscopic-lung-resection-patients-100637307","NCT07579806","Dexmedetomidine Nasal Spray on Postoperative Delirium in Elderly Thoracoscopic Lung Resection Patients","The Effect of Dexmedetomidine Nasal Spray on Postoperative Delirium in Elderly Patients Undergoing Thoracoscopic Lung Resection","Inclusion Criteria:\n\n* American Society of Anesthesiologists (ASA) physical status II-III.\n* Age ≥ 65 years, with no gender restriction.\n* Patients scheduled for elective thoracoscopic lung resection under general anesthesia, with an expected operative duration of 1-4 hours.\n* Body mass index (BMI) between 18 kg\u002Fm² and 30 kg\u002Fm².\n\nExclusion Criteria:\n\n* Known hypersensitivity to dexmedetomidine hydrochloride or any of the excipients in the investigational product.\n* Pre-existing nasal conditions, nasal surgery, or nasal allergies that may significantly impair nasal drug absorption (e.g., chronic nasal congestion, rhinorrhea, epistaxis, nasal anatomical abnormalities, or mucosal pathology affecting absorption).\n* History of cranial trauma.\n* Pre-existing diagnosis or clinical suspicion of neurocognitive impairment, defined as a Mini-Mental State Examination (MMSE) score \\\u003C 24.\n* History of schizophrenia, epilepsy, Parkinson's disease, or myasthenia gravis.\n* History of alcohol or substance abuse\u002Fdependence.\n* Left ventricular ejection fraction \\\u003C 30%; sick sinus syndrome; severe sinus bradycardia (\\\u003C 50 bpm); or second- or higher-degree atrioventricular block without permanent pacemaker implantation.\n* History of myocardial infarction, unstable angina, severe cardiac arrhythmia, or decompensated cardiac insufficiency.\n* Asthma, emphysema, chronic bronchitis, or chronic obstructive pulmonary disease (COPD) considered inappropriate for study participation by the investigator.\n* Severe hepatic impairment (Child-Pugh Class C).\n* Severe renal dysfunction requiring preoperative dialysis.\n* Inability to provide valid informed consent due to cultural background, language barrier, or cognitive impairment.\n* Refusal to sign the informed consent form.\n* Other conditions deemed inappropriate for study participation by the investigator.",true,"65 Years",{"count":171,"type":22},264,[63],"This clinical trial is designed to observe the effect of dexmedetomidine nasal spray on the incidence of postoperative delirium in elderly patients undergoing thoracoscopic lung resection. Eligible elderly patients scheduled for thoracoscopic lung resection will be randomly divided into two groups: the dexmedetomidine group will receive dexmedetomidine hydrochloride nasal spray, while the placebo group will be administered an equivalent volume of placebo nasal spray. The primary outcome is the incidence of postoperative delirium within 3 days after surgery. Secondary outcomes include the severity and duration of delirium, as well as postoperative pain, subjective sleep quality, and the incidence of adverse events, which will be compared between the two groups to evaluate the safety and efficacy of dexmedetomidine nasal spray.",[175],"Postoperative Delirium (POD)",[177,178,179,180,175],"Dexmedetomidine Nasal Spray","Elderly (people aged 65 or more)","Video-assisted thoracoscopic surgery (VATS)","Lung resection procedures","2026-05-06",{"date":155,"type":43},{"date":184,"type":22},"2026-06-01",{"date":186,"type":22},"2026-12-31",{"name":49,"class":50},{"id":189,"slug":190,"hasResults":12,"nctId":191,"briefTitle":192,"officialTitle":193,"acronym":4,"eligibilityCriteria":194,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":195,"enrollmentInfo":196,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":197,"conditions":198,"keywords":201,"overallStatus":130,"whyStopped":4,"lastUpdateSubmitDate":204,"lastUpdatePostDateStruct":205,"startDateStruct":207,"completionDateStruct":209,"leadSponsor":211,"locationsCount":51},"100568038","a-multi-center-open-label-prospective-study-on-early-initiation-of-targeted-release-formulation-of-budesonide-in-patients-with-primary-iga-nephropathy-100568038","NCT06676007","A Multi-center Open Label Prospective Study on Early Initiation of Targeted-release Formulation of Budesonide in Patients With Primary IgA Nephropathy","A Multicenter Open Label Prospective Study on Early Initiation of Targeted-release Formulation of Budesonide in Patients With Primary IgA Nephropathy","Inclusion Criteria:\n\n1. Target patients aged 18-75, including those aged 18 and 75\n2. Primary IgA nephropathy diagnosed by renal biopsy within 3 months\n3. eGFR≥30ml\u002Fmin\u002F1.73m2\n4. 24-hour urine protein ≥ 1.0g\u002Fd, or UPCR ≥ 0.8 g\u002Fg\n5. Sign informed consent\n\nExclusion Criteria:\n\n1. Including but not limited to secondary IgAN caused by allergic purpura, systemic lupus erythematosus, cirrhosis, rheumatoid arthritis, and ankylosing spondylitis\n2. Patients who have received kidney transplantation or dialysis\n3. Patients with other glomerular diseases (such as C3 glomerular disease and\u002For diabetes nephropathy) and nephrotic syndrome (i.e. proteinuria\\>3.5 g\u002Fd, serum albumin\\\u003C3.0 g\u002Fdl, with or without edema)\n4. Patients with acute, chronic, or potential infectious diseases, including hepatitis, tuberculosis, human immunodeficiency virus, and chronic urinary tract infections\n5. Patients with type 1 or type 2 diabetes diagnosed and poorly controlled (HbA1c\\>8%)\n6. Patients with a history of unstable angina, grade III or IV congestive heart failure, and\u002For clinically significant arrhythmias\n7. Patients with poor blood pressure control (systolic blood pressure ≥ 140mmHg or diastolic blood pressure ≥ 90mmHg)\n8. Patients diagnosed with malignant tumors within the past 5 years\n9. Patients with known glaucoma, known cataracts, and\u002For a history of cataract surgery\n10. Gastrointestinal diseases that may interfere with the study of drug efficacy or release, such as peptic ulcer disease, inflammatory bowel disease, and chronic diarrhea\n11. Patients with severe adverse reactions to steroids in the past, including psychiatric symptoms\n12. Patients who have received systemic immunosuppressive drug treatment within 3 months prior to enrollment\n13. Patients who have received any systemic GCS treatment within the past 3 months prior to enrollment\n14. Patients taking potent cytochrome P450 3A4 inhibitors (CYP3A4)\n15. Current or previous (within the past 2 years) alcoholism or drug abuse;\n16. Expected lifespan\\\u003C5 years\n17. During the study treatment period and 3-month follow-up period, women who are pregnant, breastfeeding, or unwilling to use highly effective contraception (contraception is only required for women with fertility potential)\n18. Researchers believe that patients who are not suitable for treatment with Nefecon","75 Years",{"count":121,"type":22},"To observe of the efficacy and safety of early initiation of budesonide enteric coated capsules in the treatment of primary IgA nephropathy.",[199,200],"IgA Nephropathy (IgAN)","Early Initial Therapy",[199,202,203,200],"Nefecon","multi-center","2026-01-13",{"date":206,"type":43},"2026-01-15",{"date":208,"type":43},"2024-10-30",{"date":210,"type":22},"2027-06-30",{"name":49,"class":50},{"id":213,"slug":214,"hasResults":12,"nctId":215,"briefTitle":216,"officialTitle":216,"acronym":4,"eligibilityCriteria":217,"healthyVolunteers":168,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":218,"targetDuration":4,"studyType":61,"phases":220,"briefSummary":221,"conditions":222,"keywords":228,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":230,"lastUpdatePostDateStruct":231,"startDateStruct":233,"completionDateStruct":235,"leadSponsor":237,"locationsCount":4},"100615893","phase-4-safety-exploration-and-evaluation-of-dexmedetomidine-hydrochloride-nasal-spray-for-pre-anesthesia-sedation-in-low-monitoring-settings-100615893","NCT07298525","Safety Exploration and Evaluation of Dexmedetomidine Hydrochloride Nasal Spray for Pre-anesthesia Sedation in Low-Monitoring Settings","Inclusion Criteria:\n\n* be 18 years of age or older, including the age of 18; no gender limitation;\n* American Society of Anesthesiologists (ASA) grade I to III;\n* Require general anesthesia, intraspinal anesthesia, or nerve block anesthesia for an elective surgical procedure;\n* Provide informed consent for participation in this study prior to the commencement of the trial and execute a written document of informed consent willingly.\n\nExclusion Criteria:\n\n* Individuals with a known hypersensitivity to dexmedetomidine hydrochloride or any excipient; patients with a documented allergy to any tranquilizers, opioids, or other substances employed in the trial;\n* Individuals with airway hyperactivity, such as those suffering from chronic obstructive pulmonary disease (COPD), asthma, or sleep apnea, who are determined by the researchers to have experienced or are experiencing safety concerns related to these conditions;\n* Patients with a history of nasal disorders, previous surgical procedures, or allergic reactions deemed clinically significant by the research team, which could significantly impact drug absorption (e.g., chronic nasal congestion, rhinorrhea, nosebleeds, and other symptoms, as well as anatomical or mucosal abnormalities in the nose that may affect drug uptake);\n* A blood oxygen saturation (SpO2) level of less than or equal to 92% in a non-oxygenated state during the screening period;\n* patients with current psychiatric disorders (like schizophrenia or depression) or cognitive impairment; those with a history of epilepsy; or individuals with a past record of psychotropic or narcotic substance abuse;\n* A history of myocardial infarction or unstable angina pectoris within the past six months prior to the screening phase;\n* A heart rate or pulse rate of less than or equal to 50 beats per minute during the screening period, the presence of clinically significant heart functional abnormalities as determined by the investigators, or the presence of grade II or higher atrioventricular block (excluding patients with implanted pacemakers) along with other severe arrhythmias;\n* Patients with inadequately controlled hypertension (systolic blood pressure ≥160 mmHg and\u002For diastolic blood pressure ≥100 mmHg during the screening period) or hypotension (systolic blood pressure ≤90 mmHg and\u002For diastolic blood pressure ≤ mmHg during the screening period);\n* Participants who have already engaged in other clinical trials and have taken the investigational drug within the three months preceding the screening period;\n* Pregnant or lactating women expected to undergo a cesarean section during labor and delivery;\n* The investigator concludes that the patient possesses other conditions rendering them ineligible for trial participation.",{"count":219,"type":22},564,[63],"The goal of this clinical trial is to assess the viability of dexmedetomidine hydrochloride nasal spray under minimal or no supervision and to further investigate novel clinical applications for this medication. This study aims to investigate the following aspects: the incidence of adverse respiratory and circulatory events requiring medical intervention following the administration of dexmedetomidine nasal spray for pre-anesthetic sedation, its sedative efficacy and onset time, and its impact on the quality of post-anesthesia recovery and the occurrence of postoperative delirium. Researchers will compare dexmedetomidine hydrochloride nasal spray to a placebo (a look-alike substance that contains no drug) to see the incidence and severity of adverse events following administration. Participants will receive either dexmedetomidine nasal spray or a placebo 45 minutes before anesthesia induction. The blinded assessor will continuously monitor and record vital signs, adverse events, and the level of sedation. More importantly, observations and records should be made for respiratory and circulatory events that require medical intervention. A follow-up assessment will be conducted within three days after the operation to evaluate the incidence of postoperative delirium and patient satisfaction.",[223,224,225,226,227],"Dexmedetomidine","Sedation","Safety","Preanesthetic Medication","Monitored Anaesthesia Care",[223,224,225,226,227,229],"Adverse Events of Respiratory Circulation","2025-12-22",{"date":232,"type":43},"2025-12-23",{"date":234,"type":22},"2026-01-10",{"date":236,"type":22},"2026-12-30",{"name":49,"class":50},{"id":239,"slug":240,"hasResults":12,"nctId":241,"briefTitle":242,"officialTitle":243,"acronym":4,"eligibilityCriteria":244,"healthyVolunteers":12,"sex":245,"minAge":19,"maxAge":246,"enrollmentInfo":247,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":249,"conditions":250,"keywords":252,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":254,"lastUpdatePostDateStruct":255,"startDateStruct":257,"completionDateStruct":259,"leadSponsor":261,"locationsCount":4},"100606423","butorphanol-for-pain-relief-after-cesarean-section-a-retrospective-study-100606423","NCT07175363","Butorphanol for Pain Relief After Cesarean Section: A Retrospective Study","The Application of Butorphanol in Postoperative Analgesia Management After Cesarean Section: A Retrospective Cohort Study","Inclusion Criteria:\n\n1. Age 18-55 years\n2. ASAI-III level\n3. Scheduled or emergency cesarean section\n4. Postoperative use of analgesic pump (formulation includes buprenorphine or tramadol or hydromorphone, etc.)\n5. Complete electronic medical records\n\nExclusion Criteria:\n\n1. Postoperative analgesia pump usage time is less than 24 hours\n2. Missing key information such as follow-up status in medical records","FEMALE","55 Years",{"count":248,"type":22},2500,"This study explored the association between postoperative functional recovery and the formula of analgesic pumps as well as other related factors (such as age, intraoperative blood loss, operation duration, etc.) by retrospectively analyzing the clinical data of patients undergoing cesarean section in the main campus and branches of Sichuan Provincial People's Hospital from September 2024 to June 2025. The value of this study lies in: 1) providing a basis for optimizing the postoperative analgesia plan after cesarean section. 2) To provide references for the formulation of personalized analgesia strategies in clinical practice, improve the postoperative recovery quality of patients, promote the concept of enhanced recovery after surgery, and reduce the medical burden.",[251],"Caesarean Section",[253],"Caesarean section","2025-09-15",{"date":256,"type":43},"2025-09-16",{"date":258,"type":22},"2025-09-20",{"date":260,"type":22},"2026-06-30",{"name":49,"class":50},{"id":263,"slug":264,"hasResults":12,"nctId":265,"briefTitle":266,"officialTitle":266,"acronym":4,"eligibilityCriteria":267,"healthyVolunteers":12,"sex":245,"minAge":19,"maxAge":268,"enrollmentInfo":269,"targetDuration":4,"studyType":61,"phases":271,"briefSummary":273,"conditions":274,"keywords":276,"overallStatus":130,"whyStopped":4,"lastUpdateSubmitDate":281,"lastUpdatePostDateStruct":282,"startDateStruct":284,"completionDateStruct":286,"leadSponsor":288,"locationsCount":51},"100601169","early-phase-1-mechanism-of-red-yeast-rice-regulating-intestinal-indole-metabolism-pathway-to-improve-chronic-inflammation-in-polycystic-ovary-syndrome-100601169","NCT07106996","Mechanism of Red Yeast Rice Regulating Intestinal Indole Metabolism Pathway to Improve Chronic Inflammation in Polycystic Ovary Syndrome","Inclusion Criteria\n\n* Female patients aged 18-40 years old\n* Meeting the Rotterdam criteria (at least two of the following):\n* Anovulation or oligo-ovulation\n* Clinical evidence of hyperandrogenism or hyperandrogenemia\n* Ultrasound findings indicating polycystic ovarian morphology (defined as at least 12 follicles measuring 2-9 mm in diameter and\u002For an ovarian volume \\>10 mL \\[length × width × thickness \u002F 2\\] in one ovary)\n* Subjects who have been fully informed of the study procedures and related risks, and voluntarily agree to participate\n\nExclusion Criteria\n\n* Pregnant women (confirmed via urine\u002Fserum hCG)\n* Patients with concomitant infectious diseases or severe dysfunction of multiple systemic organs\n* Patients who have taken antibiotics or other drugs (such as probiotics, prebiotics, etc.) that can alter the composition of intestinal flora within 3 months before enrollment","40 Years",{"count":270,"type":22},90,[272],"EARLY_PHASE1","The aim of this study is to elucidate the effects of red yeast rice on the improvement of symptoms in patients with polycystic ovary syndrome（PCOS）, and to analyze the dose-response relationship between intestinal microbiota and its metabolite, hydroxyindole, and clinical indicators of PCOS.\n\nThe main questions it aims to answer are:\n\nHow effective is red yeast rice in treating PCOS? Does the indole metabolic pathway of gut microbiota play a crucial role in the improvement of PCOS symptoms by red yeast rice? Participants will take 6 grams of red yeast rice daily for 6 months, and records will be kept of their PCOS clinical symptoms and indicators before the intervention, at the 3rd month post-intervention, and at the 6th month post-intervention. Additionally, biological samples from feces and serum will be collected at these time points.",[275],"Polycystic Ovary Syndrome (PCOS)",[277,278,279,280],"Polycystic ovary syndrome","red yeast rice","intestinal microbiota","indole metabolism","2025-08-05",{"date":283,"type":43},"2025-08-06",{"date":285,"type":43},"2025-07-28",{"date":287,"type":22},"2026-08-01",{"name":49,"class":50},{"id":290,"slug":291,"hasResults":12,"nctId":292,"briefTitle":293,"officialTitle":294,"acronym":295,"eligibilityCriteria":296,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":297,"targetDuration":4,"studyType":61,"phases":299,"briefSummary":301,"conditions":302,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":305,"lastUpdatePostDateStruct":306,"startDateStruct":308,"completionDateStruct":310,"leadSponsor":312,"locationsCount":4},"100573355","recombinant-human-brain-natriuretic-peptide-for-the-recovery-stage-of-septic-shock-100573355","NCT06745206","Recombinant Human Brain Natriuretic Peptide for the Recovery Stage of Septic Shock","Recombinant Human Brain Natriuretic Peptide for the Recovery Stage of Septic Shock: An Interventional Pilot Study","rh-BNP-RSS","Inclusion criteria:\n\n1. Age \\>18 years.\n2. Septic shock in recovery phase with decreasing vasopressor requirements, which is defined as:\n\n   1. Fulfilling the Sepsis-3 definition of septic shock at initial stage.\n   2. Hemodynamic stability achieved after adequate initial resuscitation and individualized hemodynamic optimization.\n   3. Controlled infection source with 48-hour trend of improving temperature, white blood cell count, and procalcitonin.\n   4. 48-hour trend of decreasing vasopressor requirements and transition to negative fluid balance.\n   5. Adequate perfusion with warm extremities, and capillary refill time \\\u003C3 seconds.\n3. Ongoing pulse index continuous cardiac output (PiCCO) hemodynamic monitoring and sinus rhythm.\n4. Volume indicators above the lower limit of normal range, with global end-diastolic volume index (GEDI) \\>680 mL\u002Fm2 and central venous pressure (CVP) \\>8 mmHg.\n5. Signs of cardiac dysfunction: BNP\\>200\\[10\\] or NT-proBNP \\>900 pg\u002Fml\\[6\\] or reduced ejection fraction (LVEF) \\\u003C 50%.\n6. No bolus dose of diuretics had been administered in the previous 6 hours.\n7. Informed consent obtained from patient\u002Flegal representative.\n\nExclusion Criteria:\n\n1. Pregnancy or lactation.\n2. Arrhythmia.\n3. Advanced renal dysfunction (Acute Kidney Injury \\[AKI\\] stage 3 or Chronic Kidney Disease \\[CKD\\] stage 3b or higher) based on Kidney Disease: Improving Global Outcomes (KDIGO) criteria.\n4. Inadequate ultrasound window preventing acquisition of diagnostic-quality images.\n5. Trauma or neurological diseases (including intracerebral hemorrhage and cerebral infarction).\n6. Pre-existing severe heart failure (New York Heart Association \\[NYHA\\] class III-IV) or acute myocardial infarction within the past 30 days.\n7. Concurrent enrollment in interventional trials that could confound study outcomes.\n\nCriteria for withdrawing from the study:\n\n1. Withdrawal of the informed consent.\n2. Severe hemodynamic deterioration necessitating the discontinuation of all vasodilatory medications.\n3. Treating clinician's decision.",{"count":298,"type":22},30,[300],"NA","As infection control improves and circulation stabilizes, treatment de-escalation of septic shock begins, accompanied by fluid redistribution from interstitial spaces to the vasculature, increasing cardiac volume load. Synthetic recombinant human BNP (rh-BNP) plays a role in inducing vasodilation, particularly in the venous system, alleviating cardiac congestion, and enhancing natriuresis and diuresis. Thus the investigators designed a single-center, prospective physiological study to evaluate the efficacy of standard rh-BNP infusion in reducing venous return and enhancing fluid removal, with a secondary objective of assessing the maintenance of perfusion pressure and tissue perfusion.",[303,304],"Sepsis-induced Cardiomyopathy","the Recovery Phase of Septic Shock","2025-07-23",{"date":307,"type":43},"2025-07-29",{"date":309,"type":22},"2025-12",{"date":311,"type":22},"2026-09",{"name":49,"class":50},{"id":314,"slug":315,"hasResults":12,"nctId":316,"briefTitle":317,"officialTitle":318,"acronym":4,"eligibilityCriteria":319,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":88,"enrollmentInfo":320,"targetDuration":322,"studyType":23,"phases":4,"briefSummary":323,"conditions":324,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":326,"lastUpdatePostDateStruct":327,"startDateStruct":329,"completionDateStruct":331,"leadSponsor":333,"locationsCount":4},"100599319","mechanisms-of-perioperative-systemic-inflammation-in-the-development-of-pnd-in-cirrhotic-patients-100599319","NCT07082946","Mechanisms of Perioperative Systemic Inflammation in the Development of PND in Cirrhotic Patients","Mechanism of Perioperative Systemic Inflammation-Induced Postoperative Neurocognitive Disorders in Chronic Liver Disease Patients Via Blood-Brain Barrier Disruption","Inclusion Criteria:\n\n1. Age: 18-80 years\n2. Patients with or without liver cirrhosis scheduled for upper abdominal surgery due to various clinical indications\n3. Ability to comply with the study protocol and provide informed consent\n\nExclusion Criteria:\n\n1. Comorbid severe cardiac, pulmonary, or renal diseases\n2. Patients with mental status incompatible with study participation, including:\n\n   * Psychiatric disorders\n   * Inability to communicate clearly\n3. Any condition preventing effective communication or cooperation",{"count":321,"type":22},148,"7 Days","Chronic Liver Disease (CLD) is associated with significant cognitive dysfunction, including hepatic encephalopathy (HE), which is driven by systemic inflammation and blood-brain barrier (BBB) disruption. Perioperative Neurocognitive Disorders (PND), comprising postoperative delirium (POD) and postoperative cognitive dysfunction (POCD), further exacerbate these impairments, particularly in cirrhotic patients undergoing major surgery. However, the mechanisms linking systemic inflammation, BBB dysfunction, and PND remain poorly understood. This study aimed to investigate perioperative cognitive changes and inflammatory markers in cirrhotic and non-cirrhotic patients undergoing major abdominal surgery, and to explore the effects of cirrhosis and surgical intervention on central nervous system inflammation and cognitive dysfunction using a rat model. The investigators conducted a prospective study on cirrhotic and non-cirrhotic patients undergoing major abdominal surgery. Perioperative cognitive function was assessed using validated tools, and inflammatory markers were analyzed using Olink Target protein detection and bioinformatics approaches. Additionally, the investigators established a cirrhosis model using bile duct ligation (CBDL) in rats, followed by exploratory laparotomy to evaluate behavioral performance, BBB integrity and levels of inflammatory cytokines in serum and brain tissue.",[325],"Hepatic Encephalopathy","2025-07-16",{"date":328,"type":43},"2025-07-24",{"date":330,"type":22},"2025-07-20",{"date":332,"type":22},"2025-08-31",{"name":49,"class":50},{"id":335,"slug":336,"hasResults":12,"nctId":337,"briefTitle":338,"officialTitle":339,"acronym":4,"eligibilityCriteria":319,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":88,"enrollmentInfo":340,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":342,"conditions":343,"keywords":345,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":349,"lastUpdatePostDateStruct":350,"startDateStruct":352,"completionDateStruct":354,"leadSponsor":356,"locationsCount":4},"100593899","exploring-the-mechanisms-of-postoperative-delirium-in-cirrhotic-patients-through-multi-omics-integrative-analysis-100593899","NCT07012434","Exploring the Mechanisms of Postoperative Delirium in Cirrhotic Patients Through Multi-Omics Integrative Analysis","Exploring the Mechanisms of Postoperative Delirium in Cirrhotic Patients Through Multi-Omics Integrative Analysis: An Observational Study",{"count":341,"type":22},133,"This study looks at memory problems after surgery in people with liver disease. We want to know how often these problems happen and what might cause them. The main question it aims to answer is:\n\n1. Do people with liver disease have more memory problems after stomach surgery than people without liver disease? If yes, how much more often?\n2. Are changes in stomach bacteria and body chemicals related to these memory problems?\n\nWho can join:\n\n* Adults getting stomach surgery\n* Both people with and without liver disease\n\nWhat participants will do:\n\n* Take memory tests before and after surgery\n* Give stool (poop) and blood samples before and after surgery\n\nWhy this matters:\n\nMemory problems after surgery can make recovery harder. If we find that stomach bacteria or body chemicals are involved, doctors might find new ways to prevent these problems in people with liver disease.",[344],"Liver Cirrhosis",[346,347,348],"Postoperative delirium","gut microbiota dysbiosis","metabolomics","2025-06-02",{"date":351,"type":43},"2025-06-10",{"date":353,"type":22},"2025-06-15",{"date":355,"type":22},"2025-10-30",{"name":49,"class":50},{"id":358,"slug":359,"hasResults":12,"nctId":360,"briefTitle":361,"officialTitle":361,"acronym":4,"eligibilityCriteria":362,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":363,"targetDuration":4,"studyType":61,"phases":364,"briefSummary":365,"conditions":366,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":368,"lastUpdatePostDateStruct":369,"startDateStruct":371,"completionDateStruct":373,"leadSponsor":375,"locationsCount":51},"100579233","investigating-the-retardation-effect-of-octa-guided-targeted-photocoagulation-on-the-progression-of-non-perfusion-areas-in-diabetic-retinopathy-patients-100579233","NCT06821633","Investigating the Retardation Effect of OCTA-Guided Targeted Photocoagulation on the Progression of Non-Perfusion Areas in Diabetic Retinopathy Patients","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Type 1 or Type 2 diabetes mellitus\n* Clinical dilated fundus examination and Optos imaging within 7 fields showing diabetic retinopathy (DR) lesions no more severe than severe non-proliferative diabetic retinopathy (NPDR)\n* Optical coherence tomography angiography (OCTA) demonstrating non-perfusion (NP) areas greater than 1 disc diameter (PD) in both eyes\n* Diabetic retinopathy in both eyes at the same stage, with the total NP area within the observed range of OCTA being comparable (difference less than 5 PD)\n* Absence of other ocular diseases that could lead to the formation of retinal microaneurysms\n* Absence of other ocular diseases that could lead to the formation of retinal non-perfusion areas\n* No diabetic macular edema involving the fovea\n* No history of retinal laser treatment\n* No history of intravitreal injection therapy within the past 3 months\n* No history of ocular surgery other than cataract surgery\n* Ability to cooperate with all examinations and provide informed consent\n\nExclusion Criteria:\n\n* Optical media opacity affecting OCTA imaging\n* Patients with difficulties in cooperating with laser treatment\n* Patients with renal failure, diabetic neuropathy, or severe cardiovascular diseases\n* Patients who are unlikely to complete follow-ups every 3 months, as well as those residing in other provinces\n* Patients requiring early PRP (conditions include: combined DME, planned cataract surgery, pregnancy planning, early PDR, poor follow-up compliance, severe vision loss in the other eye, poor glycemic control, poor renal function, or type 1 diabetes)\n* FFA showing NP greater than 10 PD within the ETDRS area or a total NP area greater than 75 PD, or an ischemia index greater than 35%",{"count":298,"type":22},[300],"This study aims to evaluate the impact of widefield OCTA-guided selective photocoagulation on the progression of diabetic retinopathy (DR) by comparing the control of non-perfusion (NP) areas, DR grading, and management of other DR lesions. The study is designed as a parallel randomized controlled trial. From February 2025 to August 2026, 30 diabetic patients attending the Ophthalmology Department of Sichuan Provincial People's Hospital will be enrolled. Using a simple randomization method, one eye of each patient will be assigned to the intervention group, while the contralateral eye will serve as the control, resulting in 30 eyes in each group. The intervention group will undergo OCTA-guided selective photocoagulation, specifically using a grid pattern (3x3) of spot laser applied once to the NP area, extending one spot diameter beyond the NP boundary. Each session will last 10-20 minutes. The control group will receive no treatment. The study will compare changes in NP area, DR grading progression, and control of other DR lesions at 3, 6, 9, and 12 months between the two groups.",[367],"Diabetic Retinopathy","2025-05-17",{"date":370,"type":43},"2025-05-21",{"date":372,"type":22},"2025-07-07",{"date":374,"type":22},"2026-08-07",{"name":49,"class":50},{"id":377,"slug":378,"hasResults":12,"nctId":379,"briefTitle":380,"officialTitle":381,"acronym":4,"eligibilityCriteria":382,"healthyVolunteers":12,"sex":18,"minAge":383,"maxAge":384,"enrollmentInfo":385,"targetDuration":4,"studyType":61,"phases":387,"briefSummary":388,"conditions":389,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":395,"lastUpdatePostDateStruct":396,"startDateStruct":398,"completionDateStruct":400,"leadSponsor":402,"locationsCount":51},"100574800","safety-and-efficacy-of-connecting-the-residual-ear-to-the-cartilage-scaffold-in-first--vs-second-stage-surgery-100574800","NCT06763991","Safety and Efficacy of Connecting the Residual Ear to the Cartilage Scaffold in First- vs. Second-Stage Surgery","Safety and Efficacy of Connecting the Residual Ear to the Cartilage Scaffold in First- vs. Second-Stage Surgery : a Protocl of a Randomized Controlled Trial in Non-expanded Auricular Reconstruction for Concha-type Microtia","Inclusion Criteria:\n\nAll consecutive patients between 6 and 30 years with a congenital concha-microtia8, admitted to our hospital are potentially eligible, and enrollment in the study will be based on the following criteria.\n\n1. Patients were fully informed about the purpose, modalities and risks associated with this study, signed an informed consent form and were willing to be followed up.\n2. Contrast-enhanced computed tomography (CT) scan shows he or she has 3.Patients can tolerate general anesthesia without severe chronic organic or mental illness.\n\nExclusion Criteria:\n\n1. Patients combined with other ear diseases such as ear fistula, titis media, etc.\n2. Patients receive other unrelated ear surgeries during the study\n3. Skin in the surgical area with infection, ulceration, and scarring.","6 Years","30 Years",{"count":386,"type":22},78,[300],"Eligible patients will be admitted from the outpatient clinic to complete the relevant examinations after admission（Preoperative routine examination and chest CT）. The baseline parameters will be registered when admitted to hospital, including case number, diagnosis, sex, age, height, weight, and underlying medical conditions. Patients have at least 12 hours to consider participation in the study and will be given the opportunity to ask questions about the study. Written informed consent will be obtained by the surgical resident or the surgeon after admission to the hospital.\n\nRandomization will be done by relevant member . After inclusion, patients will be allocated to one of the two study groups (First-stage Connection or Second-stage Connection) using an online randomization program. The perioperative care will be the same for all included patients.Surgery will be performed by experienced surgeons, with non-expanded ear reconstruction using autologous rib cartilage. The surgery normally comprises two stages. After each surgery, details and duration of the surgery will be documented. For each stage of surgery, patients are scheduled for visits about 3-6 months. In addition, after the total surgery, patients are to fill out 'Glasgow Benefit Inventory' and 'Patient and Observer Scar Assessment Scale'.",[390,391,71,392,393,394],"Microtia","Outcome Assessment","Surgery Related Complications Rate","Treatment Outcome","Reconstruction","2025-05-15",{"date":397,"type":43},"2025-05-16",{"date":399,"type":22},"2025-06-01",{"date":401,"type":22},"2027-02-20",{"name":49,"class":50},{"id":404,"slug":405,"hasResults":12,"nctId":406,"briefTitle":407,"officialTitle":408,"acronym":409,"eligibilityCriteria":410,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":411,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":413,"conditions":414,"keywords":4,"overallStatus":130,"whyStopped":4,"lastUpdateSubmitDate":416,"lastUpdatePostDateStruct":417,"startDateStruct":419,"completionDateStruct":421,"leadSponsor":423,"locationsCount":51},"100590428","prone-positioning-in-ards-predicting-neurological-complications-via-cerebral-hemodynamics-100590428","NCT06967285","Prone Positioning in ARDS: Predicting Neurological Complications Via Cerebral Hemodynamics","Changes in Cerebral Blood Flow Before and After Prone Position in Patients With ARDS Predict the Occurrence of Neurological Complications","PRONEBRAINAR","Inclusion Criteria:\n\n* Age≥18 years\n* Meet the diagnostic criteria for ARDS(Acute Respiratory Distress Syndrome),with PaO₂\u002FFiO₂\\\u003C150 mmHg,and requiring prone ventilation\n* Expected duration of mechanical ventilation\\>48 hours\n* Written informed consent obtained\n\nExclusion Criteria:\n\n* Presence of contraindications to prone positioning(e.g.,head and neck injuries,spinal instability,severe intracranial hypertension)\n* Severe neurological diseases(e.g.,cerebral hemorrhage,cerebral infarction,intracranial space-occupying lesions)that may affect the monitoring of cerebral hemodynamics\n* Life-threatening ARDS\n* Patients who are unable to undergo neurological assessment\n* Poor image quality or absence of images",{"count":412,"type":22},50,"Prone Positioning in ARDS: Predicting Neurological Complications via Cerebral Hemodynamics",[415],"ARDS (Moderate or Severe)","2025-05-03",{"date":418,"type":43},"2025-05-13",{"date":420,"type":43},"2025-03-19",{"date":422,"type":22},"2026-04-01",{"name":49,"class":50},{"id":425,"slug":426,"hasResults":12,"nctId":427,"briefTitle":428,"officialTitle":429,"acronym":4,"eligibilityCriteria":430,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":88,"enrollmentInfo":431,"targetDuration":4,"studyType":61,"phases":433,"briefSummary":434,"conditions":435,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":437,"lastUpdatePostDateStruct":438,"startDateStruct":440,"completionDateStruct":441,"leadSponsor":443,"locationsCount":51},"100585567","a-single-center-study-of-cm313-in-patients-with-pemphigus-100585567","NCT06904040","A Single-center Study of CM313 in Patients With Pemphigus","A Prospective, Single-Center, Single-Arm Clinical Study to Evaluate the Novel Humanized Cluster of Differentiation 38(CD38) Monoclonal Antibody (CM313) for the Treatment of Pemphigus","Inclusion Criteria:\n\n* Clinical manifestations:① Flaccid blisters and bullae on the skin that are prone to rupture.② Persistent erosions formed after the rupture of blisters and bullae.③ Blisters or erosions on the mucous membranes.④ Positive Nikolsky's sign.\n* Adult patients aged between 18 and 80 years old.\n* Moderate - to - severe pemphigus vulgaris\u002Ffoliaceus: According to the Pemphigus Disease Area Index (PDAI) score, a score of 9 - 24 indicates moderate severity, and a score of ≥25 indicates severe severity.\n\nExclusion Criteria:\n\n* Pregnant or lactating women and women planning to conceive.\n* Patients with known positive serology for HIV, syphilis, tuberculosis, hepatitis B, or hepatitis C in the active stage of the disease.\n* Patients who have received intravenous cyclophosphamide injection, plasma exchange, or immunoadsorption therapy within 8 weeks before screening and enrollment.",{"count":432,"type":22},20,[300],"A prospective, single-center, single-arm clinical study aimed to explore the efficacy and safety of the anti-CD38 monoclonal antibody CM313 combined with low-dose glucocorticoids in patients with pemphigus.",[436],"Pemphigus","2025-03-25",{"date":439,"type":43},"2025-04-01",{"date":439,"type":22},{"date":442,"type":22},"2028-04-01",{"name":49,"class":50},{"id":445,"slug":446,"hasResults":12,"nctId":447,"briefTitle":448,"officialTitle":449,"acronym":4,"eligibilityCriteria":450,"healthyVolunteers":168,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":451,"targetDuration":453,"studyType":23,"phases":4,"briefSummary":454,"conditions":455,"keywords":4,"overallStatus":130,"whyStopped":4,"lastUpdateSubmitDate":457,"lastUpdatePostDateStruct":458,"startDateStruct":460,"completionDateStruct":462,"leadSponsor":464,"locationsCount":51},"100580157","18fav45a-and-18fav1451taupetct-in-the-diagnosis-of-early-pathological-changes-of-alzheimers-disease-100580157","NCT06833645","[18F]AV45(Aβ) and [18F]AV1451(Tau)PET\u002FCT in the Diagnosis of Early Pathological Changes of Alzheimer's Disease","To Investigate the Mechanism of Novel Molecular Probe [18F]AV45(Aβ) and [18F]AV1451(Tau)PET\u002FCT in the Diagnosis of Early Pathological Changes of Alzheimer's Disease。","Inclusion Criteria:\n\n* Meet the MCI diagnostic criteria of Peterson in 2004;\n* The clinicaldementiarating Scale (CDR) score was 0.5;\n* Prominent memory loss may also be accompanied by impairment of other cognitive domains;\n* Insidious onset and slow progression;\n* Not at the level of dementia.\n\nAD entry criteria:\n\n* Meet the criteria for diagnosing dementia as described in the fourth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-R), Use the diagnostic criteria for AD from the National Institute of Neurology, Speech and Communication Disorders and Stroke - Alzheimer's Disease and Related Disorders (NINCDS-ADRDA) or the National Institute on Aging and Alzheimer's Disease Association (NIA-AA).\n* Clinical Dementia Rating Scale score was 1 point.\n\nExclusion Criteria:\n\n* Patients with a history of stroke and focal neurological signs, and imaging findings consistent with small cerebral vascular disease (Fazekas score ≥2);\n* The presence of other neurological disorders that can cause brain dysfunction (e.g., depression, brain tumors, Parkinson's disease, metabolic encephalopathy, encephalitis, multiple sclerosis, epilepsy, brain trauma, Normal facial pressure hydrocephalus);\n* The presence of other systemic diseases that can cause cognitive impairment (such as liver insufficiency, renal insufficiency, thyroid dysfunction, severe anemia, folic acid or vitamin B12 deficiency, syphilis, HIV infection, alcohol and drug abuse, etc.);\n* There is mental and neurological retardation.\n* There are other diseases that are known to cause cognitive impairment.",{"count":452,"type":22},280,"12 Months","To investigate the primary brain regions of precursors of Alzheimer's disease and Alzheimer's disease by novel molecular probe \\[18F\\]AV45(Aβ) and \\[18F\\]AV1451(Tau)PET\u002FCT imaging. And the distribution of positive lesions in the brain area affecting the simple mental state examination and the Montreal Cognitive Assessment Scale in AD patients; It is expected to provide molecular imaging information for further study of the pathogenesis of AD. After clinical transformation, objective and quantitative positive diagnostic criteria for \\[18F\\]AV45 and \\[18F\\]AV1451PET\u002FCT in the diagnosis of early Alzheimer's disease were established to avoid the defects of relying on the subjective experience of doctors and time-consuming diagnosis.",[456],"Alzheimer's Disease","2025-02-18",{"date":459,"type":43},"2025-02-19",{"date":461,"type":43},"2024-05-10",{"date":463,"type":22},"2025-02-25",{"name":49,"class":50},{"id":466,"slug":467,"hasResults":12,"nctId":468,"briefTitle":469,"officialTitle":470,"acronym":4,"eligibilityCriteria":471,"healthyVolunteers":168,"sex":18,"minAge":19,"maxAge":472,"enrollmentInfo":473,"targetDuration":4,"studyType":61,"phases":475,"briefSummary":476,"conditions":477,"keywords":4,"overallStatus":130,"whyStopped":4,"lastUpdateSubmitDate":481,"lastUpdatePostDateStruct":482,"startDateStruct":483,"completionDateStruct":485,"leadSponsor":487,"locationsCount":51},"100579088","efficacy-and-safety-of-cocktail-of-ropivacaine-for-local-infiltration-analgesia-in-patients-undergoing-laparoscopic-cholecystectomy-100579088","NCT06819748","Efficacy and Safety of Cocktail of Ropivacaine for Local Infiltration Analgesia in Patients Undergoing Laparoscopic Cholecystectomy","Efficacy and Safety of Cocktail of Ropivacaine,sodium Bicarbonate and Dexamethasone for Incision Local Infiltration Analgesia in Patients Undergoing Ambulatory Laparoscopic Cholecystectomy:A Prospective Randomized Control Trial","Inclusion Criteria:\n\n* Patients undergoing daytime laparoscopic cholecystectomy in Sichuan Provincial People's hospital ② Age: 18-70 years\n\n  * American society of Anesthesiologists physical status classification system I-II ④ 18 kg\u002F㎡≤ BMI ≤ 30 kg\u002F㎡ ⑤ No communication barriers, able to understand the research process and the use of pain scale.\n\n    * Signed informed consent\n\nExclusion Criteria:\n\n* Drug allergy related to this study\n\n  * History of chronic pain, long-term use of analgesic drugs (equivalent to ≥ 10mg oxycodone per day), alcohol abuse, gastrointestinal bleeding or perforation after application of non steroidal anti-inflammatory drugs\n\n    * Patients with ischemic heart disease, peripheral arterial vascular or cerebrovascular disease, or patients with pulmonary heart disease, active peptic ulcer or gastrointestinal bleeding, or patients with inflammatory bowel disease\n\n      * Patients taking monoamine oxidase inhibitors or within 2 weeks after discontinuation ⑤ Preoperative pain score (NRS ) was greater than or equal to 4 points ⑥ Participated in other clinical studies within three months","70 Years",{"count":474,"type":22},210,[300],"The goal of this clinical trial is to learn if the use of cocktail of ropivacaine,sodium bicarbonate and dexamethasone for incision local infiltration analgesia in patients undergoing ambulatory laparoscopic cholecystectomy is safe and effective. The main questions it aims to answer are:\n\nDoes the cocktail lower the The incidence of moderate to severe pain during movement stages within six hours after surgery.\n\nResearchers will compare the cocktail to ropivacaine for incision local infiltration analgesia to see if the cocktail works to moderate the postoperative pain of ambulatory laparoscopic cholecystectomy patients.\n\nParticipants will:\n\nReceive the cocktail or ropivacaine for incision local infiltration analgesia at the end of the surgery.\n\nAnswer the questions about postsurgical pain at rest or during motion(using a Numeric Rating Scale (NRS) of 0 to 10. Pain measurements were performed at 2, 6, 12, 24 hours,3,7,30 days and 3 months postoperatively.",[478,479,480],"Cholecystectomy, Laparoscopic","Ambulatory Surgical Procedures","Multimodal Analgesia","2025-02-16",{"date":459,"type":43},{"date":484,"type":43},"2025-02-14",{"date":486,"type":22},"2025-09-01",{"name":49,"class":50},{"id":489,"slug":490,"hasResults":12,"nctId":491,"briefTitle":492,"officialTitle":493,"acronym":4,"eligibilityCriteria":494,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":495,"targetDuration":4,"studyType":61,"phases":496,"briefSummary":497,"conditions":498,"keywords":4,"overallStatus":130,"whyStopped":4,"lastUpdateSubmitDate":499,"lastUpdatePostDateStruct":500,"startDateStruct":501,"completionDateStruct":503,"leadSponsor":505,"locationsCount":51},"100576402","nursing-interventions-for-alzheimers-patients-during-petct-imaging-100576402","NCT06784830","Nursing Interventions for Alzheimer's Patients During PET\u002FCT Imaging","Enhancing Nursing Interventions for Alzheimer's Patients During PET\u002FCT Imaging: Effects on Image Quality and Patient Satisfaction","Inclusion Criteria:\n\n* Meet the criteria for diagnosing dementia as described in the fourth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-R), Use the diagnostic criteria for AD from the National Institute of Neurology, Speech and Communication Disorders and Stroke - Alzheimer's Disease and Related Disorders (NINCDS-ADRDA) or the National Institute on Aging and Alzheimer's Disease Association (NIA-AA).\n\nExclusion Criteria:\n\n* Patients with a history of stroke and focal neurological signs, and imaging findings consistent with small cerebral vascular disease (Fazekas score ≥2);\n* The presence of other neurological disorders that can cause brain dysfunction (e.g., depression, brain tumors, Parkinson's disease, metabolic encephalopathy, encephalitis, multiple sclerosis, epilepsy, brain trauma, Normal facial pressure hydrocephalus);\n* The presence of other systemic diseases that can cause cognitive impairment (such as liver insufficiency, renal insufficiency, thyroid dysfunction, severe anemia, folic acid or vitamin B12 deficiency, syphilis, HIV infection, alcohol and drug abuse, etc.);\n* There is mental and neurological retardation.\n* There are other diseases that are known to cause cognitive impairment.",{"count":121,"type":22},[300],"The impact of nursing Interventions during PET\u002FCT imaging in Alzheimer's patients on image quality and patient satisfaction will be assessed in 200 patients.",[456],"2025-02-13",{"date":484,"type":43},{"date":502,"type":43},"2024-06-15",{"date":504,"type":22},"2025-02-20",{"name":49,"class":50},{"id":507,"slug":508,"hasResults":12,"nctId":509,"briefTitle":510,"officialTitle":511,"acronym":4,"eligibilityCriteria":512,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":513,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":515,"conditions":516,"keywords":4,"overallStatus":130,"whyStopped":4,"lastUpdateSubmitDate":517,"lastUpdatePostDateStruct":518,"startDateStruct":520,"completionDateStruct":522,"leadSponsor":524,"locationsCount":51},"100579062","efficacy-and-safety-of-amphotericin-b-and-azoles-in-the-treatment-of-invasive-fungal-disease-100579062","NCT06819410","Efficacy and Safety of Amphotericin B and Azoles in the Treatment of Invasive Fungal Disease","A Retrospective Clinical Study on the Efficacy and Safety of Amphotericin B Compared With Azoles in the Treatment of Invasive Fungal Disease","Inclusion Criteria:\n\n* There is no age limit, gender is not limited\n* Patients with invasive fungal disease who are treated with polyene antifungals or azole antifungals should be treated for ≥ 7 days.\n\nExclusion Criteria:\n\n* Patients with incomplete data or other factors affecting the clinical outcome judgement\n* Patients who are judged by the investigator to be unsuitable to participate in this study.",{"count":514,"type":22},1000,"Efficacy and safety of amphotericin B and azoles in the treatment of invasive fungal disease",[31],"2025-02-10",{"date":519,"type":43},"2025-02-11",{"date":521,"type":43},"2021-05-01",{"date":523,"type":22},"2025-02-01",{"name":49,"class":50},{"id":526,"slug":527,"hasResults":12,"nctId":528,"briefTitle":529,"officialTitle":529,"acronym":4,"eligibilityCriteria":530,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":195,"enrollmentInfo":531,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":533,"conditions":534,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":540,"lastUpdatePostDateStruct":541,"startDateStruct":543,"completionDateStruct":544,"leadSponsor":546,"locationsCount":4},"100567346","real-world-pharmacokineticpharmacodynamic-study-of-eravacycline-in-critically-iii-patients-100567346","NCT06666998","Real-World Pharmacokinetic\u002FPharmacodynamic Study of Eravacycline in Critically III Patients","Inclusion Criteria:\n\n* Adult male or female aged 18-75 years\n* Not respond to initial empirical treatment, treatment time to reach Eravacycline steady-state concentration\n* Empirical antimicrobial treatment is ineffective\n* Eravacycline application for ≥ 3 days\n* Understand and sign informed consent\n\nExclusion Criteria:\n\n* Urinary tract infection\n* Allergic to Eravacycline, Tigecycline antibiotics or any excipients or have previously experienced serious adverse reactions\n* Any unstable or potentially endangering the safety of the subject and their compliance with the study as judged by the investigator; comorbidities or social circumstances that can make the subject unable to follow the study plan or even endanger the safety of the patient\n* Patients expected to survive for no longer than 48h.",{"count":532,"type":22},100,"The aim of this study is to evaluate the efficacy of Eravacycline in the treatment of patients with bacterial infection and to assess the pharmacokinetics of Eravacycline and to establish a population pharmacokinetic model of Eravacycline.",[535,536,537,538,539],"Eravacycline","Pharmacokinetics","Bacteria Infection","Bacterial Resistance to Antimicrobial","Empirical Antimicrobial Therapy","2024-11-01",{"date":542,"type":43},"2024-11-04",{"date":540,"type":22},{"date":545,"type":22},"2026-11-01",{"name":49,"class":50},{"id":548,"slug":549,"hasResults":12,"nctId":550,"briefTitle":551,"officialTitle":552,"acronym":4,"eligibilityCriteria":553,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":88,"enrollmentInfo":554,"targetDuration":4,"studyType":61,"phases":556,"briefSummary":557,"conditions":558,"keywords":4,"overallStatus":130,"whyStopped":4,"lastUpdateSubmitDate":560,"lastUpdatePostDateStruct":561,"startDateStruct":563,"completionDateStruct":565,"leadSponsor":567,"locationsCount":51},"100534770","titration-of-inspired-oxygen-to-decrease-the-incidence-of-postoperative-pulmonary-complications-100534770","NCT06243146","Titration of Inspired Oxygen to Decrease the Incidence of Postoperative Pulmonary Complications","Titration of Inspired Oxygen During One-lung Ventilation to Decrease the Incidence of Postoperative Pulmonary Complications: a Randomized Controlled Trial","Inclusion Criteria:\n\n* ① General anesthesia with left bronchial tube intubation; ② Age range from 18 to 80 years old; ③ 18 kg\u002Fm2 ≤ BMI ≤ 30 kg\u002Fm2; ④ ASA grade I to III; ⑤ Individuals willing to participate in research and sign an informed consent form.\n\nExclusion Criteria:\n\n* ① CT scan indicates preoperative pulmonary infection, atelectasis, and pneumothorax; ② History of respiratory system diseases (COPD, bronchiectasis, pulmonary alveoli, interstitial lung disease, etc.); ③ Previous history of lung surgery; ④ First second forced expiratory volume\u002Festimated value (FEV1%)\\\u003C60%; ⑤ PaO2\\\u003C60mmhg (1 mmhg=0.133 kpa) or PaO2\u002FFiO2\\\u003C300mmhg or SpO2\\\u003C90% in the suction state; ⑥ History of acute upper respiratory tract infection, acute lung injury, acute respiratory distress syndrome, or respiratory failure within 3 months prior to surgery; ⑦ Combined heart failure (NYHA heart function grading ≥ 3); ⑧ Previous history of stroke and cerebral infarction; ⑨ Severe liver dysfunction (liver failure or Child Pugh score B or C) Chronic renal failure (glomerular filtration rate\\\u003C30 ml\u002Fmin) Suffering from mental illness, etc., which is not suitable for the author; æ Individuals who have participated in other clinical trials as subjects within the three months prior to participating in the study The patient refused to participate in the study.",{"count":555,"type":22},156,[300],"Lung cancer is with the highest incidence rate and mortality among people over 60 years old in China. Postoperative pulmonary complications (PPCs) is the most common complication after pneumonectomy, which has a significant impact on the short-term and long-term prognosis of patients, and is even the primary risk factor leading to early postoperative death. High fraction of inspired oxygen (FiO2) is an independent risk factor for PPCs, but it is difficult to achieve oxygenation while avoiding hyperxemia during one lung ventilation (OLV).\n\nWe will randomly divide patients who plan to undergo thoracoscopic pulmonary resection into two groups. During OLV, titration will be used to determine the optimal FiO2 for titration group while FiO2 of 80% will be used for mechanical ventilation for control group. The incidence of postoperative PPCs, hypoxia\u002Fhyperxemia, severity level of postoperative PPC, postoperative 30 day PPC, increased hospitalization costs, and prolonged hospital stay will be observed in both groups of patients.We will evaluate the effectiveness and safety of titrating inhaled oxygen concentration in lung protection during OLV.",[559],"Unrecognized Condition","2024-10-29",{"date":562,"type":43},"2024-10-31",{"date":564,"type":43},"2024-06-20",{"date":566,"type":22},"2025-12-31",{"name":49,"class":50},{"id":569,"slug":570,"hasResults":12,"nctId":571,"briefTitle":572,"officialTitle":573,"acronym":4,"eligibilityCriteria":574,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":575,"enrollmentInfo":576,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":578,"conditions":579,"keywords":4,"overallStatus":130,"whyStopped":4,"lastUpdateSubmitDate":586,"lastUpdatePostDateStruct":587,"startDateStruct":589,"completionDateStruct":591,"leadSponsor":593,"locationsCount":51},"100553890","clinical-outcomes-and-inflammatory-responses-in-viral-vs-bacterial-sepsis-100553890","NCT06491966","Clinical Outcomes and Inflammatory Responses in Viral vs. Bacterial Sepsis","Comparative Analysis of Clinical Outcomes and Inflammatory Responses in Viral Versus Bacterial Sepsis: A Retrospective Cohort Study in ICU Patients","Inclusion Criteria:\n\n1. Patients diagnosed with sepsis according to Sepsis 3.0 criteria.\n2. Patients with confirmed bacterial sepsis based on positive bacterial cultures.\n3. Patients with confirmed viral sepsis, specifically COVID-19, diagnosed via RT-PCR for SARS-CoV-2 for viral group and negative for bacterial group.\n4. Patients aged 18 years and older.\n5. Patients admitted to the ICU during the study period.\n\nExclusion Criteria:\n\n1. Patients with mixed bacterial and viral infections.\n2. Patients with sepsis not meeting the Sepsis 3.0 criteria.\n3. Patients who received immunomodulatory therapies other than standard treatments (e.g., investigational drugs).\n4. Pregnant or breastfeeding women.","90 Years",{"count":577,"type":22},300,"This observational cohort study aims to compare clinical outcomes and inflammatory responses between patients with viral sepsis, specifically COVID-19-associated sepsis, and those with bacterial sepsis. Conducted at Sichuan Provincial People's Hospital, the study will retrospectively analyze data from ICU patients admitted between July 2021 and December 2023. The primary objective is to identify reliable biomarkers and diagnostic methods to improve patient outcomes through personalized diagnostic and therapeutic strategies.",[127,580,581,582,583,584,585],"Sepsis Bacterial","Viral Sepsis","Inflammatory Response","Cytokine Storm","COVID-19","MODS","2024-07-08",{"date":588,"type":43},"2024-07-09",{"date":590,"type":43},"2024-04-02",{"date":592,"type":22},"2024-07-10",{"name":49,"class":50},{"id":595,"slug":596,"hasResults":12,"nctId":597,"briefTitle":598,"officialTitle":598,"acronym":599,"eligibilityCriteria":600,"healthyVolunteers":12,"sex":18,"minAge":268,"maxAge":88,"enrollmentInfo":601,"targetDuration":4,"studyType":61,"phases":603,"briefSummary":604,"conditions":605,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":609,"lastUpdatePostDateStruct":610,"startDateStruct":612,"completionDateStruct":614,"leadSponsor":616,"locationsCount":51},"100534769","phase-4-pair-antiplatelet-therapy-in-ischemic-stroke-with-intracranial-artery-stenosis-100534769","NCT06243133","Pair Antiplatelet THerapy in Ischemic Stroke With Intracranial Artery Stenosis","PATH-ICAS","Inclusion Criteria:\n\n1. Age 40 \\~ 80 years old;\n2. Patients diagnosed as non-cardiogenic cerebral infarction according to the WHO definition of stroke, with MRA\u002FCTA\u002FDSA confirmed intracranial artery stenosis ≥50% (intracranial carotid artery, M1 and proximal M2 segment of middle cerebral artery, A1 and A2 segment of anterior cerebral artery, P1 and P2 segment of posterior cerebral artery, intracranial vertebral artery and basilar artery);\n3. First stroke onset within 7 days;\n4. NIHSS score ≤5;\n5. Patients or family members sign informed consent forms;\n\nExclusion Criteria:\n\n1. Patients receiving thrombolysis or endovascular therapy;\n2. Patients with recurrent stroke;\n3. Patients has undergone major surgery or major trauma within the past 30 days;\n4. History of gastrointestinal bleeding, active peptic ulcer, intracranial hemorrhage or other hemorrhagic diseases;\n5. Contraindications or intolerances to the use of antiplatelet therapeutics;\n6. Platelet count \\\u003C100\\*109\u002FL, hemoglobin\\\u003C110g\u002FL;\n7. Patients with severe organ insufficiency or other serious disease (e.g., severe cardiopulmonary failure, advanced tumor, severe dementia);\n8. Patients intolerant to MRI scan are replaced by CT or DSA;\n9. poor compliance, unable to meet the requirements of the study.",{"count":602,"type":22},1100,[63],"The goal of this clinical trial is to learn about efficacy and safety of dual antiplatelet therapy in ischemic stroke with intracranial artery stenosis. The main question it aims to answer are:\n\nwhether aspirin combined with clopidogrel for 3 month is better than 1 months for patients with non-cardiogenic cerebral infarction with intracranial artery stenosis.\n\nParticipants will get dual antiplatelet therapy (aspirin plus clopidogrel) for 1 month or 3 months within 7 days of the first stroke.\n\nResearchers will compare experimental group (3 months dual antiplatelet therapy) with comparison group (1 month dual antiplatelet therapy), to see if experimental group would reduce stroke recurrence or mortality, and increase bleeding and other adverse prognosis.",[66,606,607,608],"Intracranial Arteriosclerosis","Secondary Prevention","Antiplatelet Drug","2024-06-17",{"date":611,"type":43},"2024-06-18",{"date":613,"type":22},"2024-07-01",{"date":615,"type":22},"2026-03-31",{"name":49,"class":50},""]